胰高血糖素样肽-1受体激动剂在心力衰竭全谱中的应用
本综述总结了GLP-1受体激动剂(GLP-1 RA)在不同心力衰竭风险患者中的证据,重点关注心力衰竭。作者建议在启动GLP-1 RA前进行积极的心力衰竭筛查(包括定向临床病史、体格检查、超声心动图和利钠肽),并根据心力衰竭类型提出治疗决策建议。
要点
- 建议在启动GLP-1 RA前进行积极的心力衰竭筛查(定向病史、体格检查、超声心动图和利钠肽)。
- 无心力衰竭的2型糖尿病患者,GLP-1 RA应降低心肌梗死和卒中风险,可能减少心力衰竭住院风险。
- 射血分数降低的心力衰竭患者,使用GLP-1 RA需谨慎,因可能增加心力衰竭事件和心律失常风险。
核心结论
- 作者建议在启动GLP-1 RA前进行积极的心力衰竭筛查,并根据心力衰竭类型制定治疗决策。
研究设计与样本
- 本文为综述,检索并总结了GLP-1 RA在心力衰竭风险谱中的证据。
主要发现
- 无心力衰竭的2型糖尿病患者,GLP-1 RA应降低心肌梗死和卒中风险,可能减少心力衰竭住院风险。
- 射血分数保留的心力衰竭患者,GLP-1 RA不减少心力衰竭住院,但可能减少动脉粥样硬化事件,可个体化考虑使用。
- 射血分数降低的心力衰竭患者,使用GLP-1 RA需谨慎,因可能增加心力衰竭事件和心律失常风险,有待进一步研究提供风险-获益数据。
关键数值与推荐
- 作者建议:启动GLP-1 RA前进行心力衰竭筛查(定向临床病史、体格检查、超声心动图和利钠肽)。
- 作者建议:无心力衰竭的2型糖尿病患者,GLP-1 RA用于降低心肌梗死和卒中风险。
- 作者建议:射血分数保留的心力衰竭患者,GLP-1 RA可个体化考虑使用。
- 作者建议:射血分数降低的心力衰竭患者,使用GLP-1 RA需谨慎。
临床怎么用
- 启动GLP-1 RA前应进行心力衰竭筛查,包括定向临床病史、体格检查、超声心动图和利钠肽。
- 根据心力衰竭类型(无心力衰竭、射血分数保留、射血分数降低)决定GLP-1 RA的使用策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RAs may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across a patient's risk with a particular focus on HF. After a careful review of the literature, we challenge the current views about the use of GLP-1 RAs and suggest performing active HF screening (with directed clinical history, physical examination, an echocardiogram, and natriuretic peptides) before initiating a GLP-1 RA. After HF screening, we suggest GLP-1 RA treatment decisions as follows: (1) in people with T2D without HF, GLP-1 RAs should be used for reducing the risk of myocardial infarction and stroke, with a possible effect to reduce the risk of HF hospitalizations; (2) in patients with HF and preserved ejection fraction, GLP-1 RAs do not reduce HF hospitalizations but may reduce atherosclerotic events, and their use may be considered in an individualized manner; and (3) in patients with HF and reduced ejection fraction, the use of GLP-1 RAs warrants caution due to potential risk of worsening HF events and arrhythmias, pending risk-benefit data from further studies.
引用
- Ferreira JP, Sharma A, Butler J, et al. Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. J Clin Endocrinol Metab. 2023. PMID: 37409733. doi:10.1210/clinem/dgad398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。